（编辑 王雪儿） 证券日报网讯 三鑫医疗8月13日发布公告，在公司回答调研者提问时表示，公司自主研发并作为国产品 牌首次获得审批注册的一次性使用血液透析器（湿膜，高通量/非高通量），作为普通透析器迭代升级 产品服务于广大透析患者，其以先进的透析膜湿化填充工艺和更加优异的生物相容性，减少了过敏反 应，提升了患者的透析体验和生存质量，该产品与PP、PC材质高通量、非高通量"干膜"透析器，共同 构成国产品牌血液透析器最齐全的产品群。公司正稳步推进湿膜透析器在各地区的市场准入和入院工 作，全力做好与医保的配合、与集采政策的衔接，通过差异化的竞争策略提升血液透析器的市场份额， 不断扩大湿膜透析器的临床应用。 ...

Financial Performance - The company achieved operating revenue of 760.81 million CNY, a year-on-year increase of 10.83% [3] - Net profit attributable to shareholders reached 115.12 million CNY, up 8.35% from the previous year [3] - Net profit excluding non-recurring gains and losses was 103.23 million CNY, reflecting a growth of 9.26% [3] - The net profit growth rate after excluding share payment expenses was 13.60% [3] Business Segments - Blood purification products generated revenue of 625.59 million CNY, a 19.73% increase, accounting for 82.23% of total revenue [3] - Drug delivery devices saw revenue of 82.41 million CNY, a decline of 15.06%, representing 10.83% of total revenue [3] - Cardiothoracic products achieved revenue of 34.98 million CNY, a slight increase of 0.74%, making up 4.60% of total revenue [3] International Market Expansion - The company successfully registered products in Indonesia, Peru, and Mexico, and is advancing certification processes in Turkey, Vietnam, and Brazil [4][6] - Overseas revenue reached 187.00 million CNY, a significant increase of 67.30%, driven by blood purification product exports [4][6] - Blood purification product exports accounted for 88% of total export revenue, with sales increasing by 83.84% [6] Research and Development - R&D investment totaled 36.98 million CNY, with over 30 projects underway and 11 new patents authorized [4][5] - The company is focusing on innovative medical devices and high-value consumables, including artificial blood vessels and anticoagulant-coated catheters [5][15] Future Outlook - The number of patients receiving hemodialysis in China is projected to grow from 248,000 in 2012 to 1.0273 million by 2024, indicating a 4.1-fold increase [9] - The dialysis treatment rate in China is currently below 30%, compared to 58% in the U.S., suggesting significant growth potential [9] - The company plans to expand production capacity and enhance product offerings to meet increasing market demand [15] Shareholder Returns - The company has implemented a stable profit distribution policy, with cumulative cash dividends amounting to 547 million CNY since its IPO [16] - A three-year shareholder return plan (2025-2027) aims to distribute at least 30% of the annual distributable profits in cash [16]